CL2017000595A1 - Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular - Google Patents

Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular

Info

Publication number
CL2017000595A1
CL2017000595A1 CL2017000595A CL2017000595A CL2017000595A1 CL 2017000595 A1 CL2017000595 A1 CL 2017000595A1 CL 2017000595 A CL2017000595 A CL 2017000595A CL 2017000595 A CL2017000595 A CL 2017000595A CL 2017000595 A1 CL2017000595 A1 CL 2017000595A1
Authority
CL
Chile
Prior art keywords
monoclonal antibody
enzymatic activity
inhibits
humanized monoclonal
vascular endothelial
Prior art date
Application number
CL2017000595A
Other languages
English (en)
Inventor
Shoichi Naito
Hiroaki Aino
Etsuo Nakamura
Sunao Imai
Yamane Shoji
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55459146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000595(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of CL2017000595A1 publication Critical patent/CL2017000595A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>UN ANTICUERPO MONOCLONAL HUMANIZADO, O UN FRAGMENTO DE ESTE, QUE INHIBE DE MANERA SELECTIVA LA ACTIVIDAD ENZIMÁTICA DE LA LIPASA ENDOTELIAL VASCULAR, Y COMPOSICIONES FARMACÉUTICAS QUE LO CONTIENEN COMO INGREDIENTE ACTIVO, ÚTILES PARA EL TRATAMIENTO DE LA ARTERIOESCLEROSIS O EL SÍNDROME METABÓLICO.</p>
CL2017000595A 2014-09-11 2017-03-10 Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular CL2017000595A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014184710 2014-09-11

Publications (1)

Publication Number Publication Date
CL2017000595A1 true CL2017000595A1 (es) 2017-11-03

Family

ID=55459146

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000595A CL2017000595A1 (es) 2014-09-11 2017-03-10 Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular

Country Status (18)

Country Link
US (2) US10570215B2 (es)
EP (1) EP3192813A4 (es)
JP (2) JP6635599B2 (es)
KR (1) KR102520286B1 (es)
CN (1) CN107074963B (es)
AR (1) AR101811A1 (es)
AU (1) AU2015313179B2 (es)
CA (1) CA2960994C (es)
CL (1) CL2017000595A1 (es)
EA (1) EA036324B1 (es)
IL (1) IL250981B (es)
MX (1) MX388559B (es)
MY (1) MY181835A (es)
PH (1) PH12017500461B1 (es)
SG (2) SG10201900605SA (es)
TW (2) TWI734410B (es)
WO (1) WO2016039402A1 (es)
ZA (1) ZA201702489B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180021705A (ko) * 2015-06-30 2018-03-05 시애틀 지네틱스, 인크. 항-ntb-a 항체 및 관련 조성물 및 방법
CN111263769B (zh) * 2017-07-10 2024-01-02 先天制药公司 Siglec-9中和性抗体
EP3712170A4 (en) * 2017-11-10 2022-03-02 Jiangsu Hengrui Medicine Co., Ltd. CD96 ANTIBODY, ANTIGEN BINDING FRAGMENT AND PHARMACEUTICAL USE THEREOF
TWI887293B (zh) * 2019-11-07 2025-06-21 美商麥迪紐有限責任公司 用於治療心血管疾病之內皮脂酶抗體
CN115297838A (zh) * 2020-02-24 2022-11-04 麦迪穆医学免疫有限责任公司 抗内皮脂肪酶抗体的制剂
CN114437216A (zh) * 2020-11-05 2022-05-06 上海津曼特生物科技有限公司 抗Siglec-15抗体及其在制备药物中的应用
CN122580346A (zh) * 2023-11-21 2026-08-14 布里格姆妇女医院 Klrb1结合剂及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH062075B2 (ja) * 1988-04-30 1994-01-12 大日本製薬株式会社 抗ヒトポストヘパリンプラズマ由来リポ蛋白リパーゼモノクローナル抗体およびその製造方法
AU750891B2 (en) * 1996-12-06 2002-08-01 Aventis Pharmaceuticals Inc. Polypeptides encoded by a human lipase-like gene, compositions and methods
WO1999032611A1 (en) * 1997-12-19 1999-07-01 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use
CA2363486C (en) 1999-03-26 2012-12-18 Michael Jaye Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol
WO2013054830A1 (ja) * 2011-10-12 2013-04-18 塩野義製薬株式会社 Ｅｌの酵素活性を阻害するｅｌに対するモノクローナル抗体
SG10201707233UA (en) * 2013-03-14 2017-10-30 Shionogi & Co Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase

Also Published As

Publication number Publication date
US10570215B2 (en) 2020-02-25
BR112017004429A2 (pt) 2018-02-27
KR102520286B1 (ko) 2023-04-10
CA2960994C (en) 2025-07-08
CA2960994A1 (en) 2016-03-17
AU2015313179B2 (en) 2020-10-22
EP3192813A4 (en) 2018-08-01
WO2016039402A1 (ja) 2016-03-17
JP2020059743A (ja) 2020-04-16
JP6635599B2 (ja) 2020-01-29
KR20170052655A (ko) 2017-05-12
TW202026313A (zh) 2020-07-16
JPWO2016039402A1 (ja) 2017-06-22
PH12017500461A1 (en) 2017-07-31
IL250981A0 (en) 2017-04-30
ZA201702489B (en) 2018-08-29
PH12017500461B1 (en) 2023-07-19
TW201613982A (en) 2016-04-16
TWI734410B (zh) 2021-07-21
AU2015313179A1 (en) 2017-03-30
IL250981B (en) 2020-06-30
EP3192813A1 (en) 2017-07-19
AR101811A1 (es) 2017-01-11
US20170260290A1 (en) 2017-09-14
CN107074963A (zh) 2017-08-18
MX388559B (es) 2025-03-20
EA036324B1 (ru) 2020-10-27
TWI688575B (zh) 2020-03-21
US11136411B2 (en) 2021-10-05
MX2017002968A (es) 2017-06-15
MY181835A (en) 2021-01-08
SG11201701762VA (en) 2017-04-27
SG10201900605SA (en) 2019-02-27
US20200071424A1 (en) 2020-03-05
CN107074963B (zh) 2021-07-16
EA201790590A1 (ru) 2017-08-31
JP6827255B2 (ja) 2021-02-10

Similar Documents

Publication Publication Date Title
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
PT3635009T (pt) Composições e métodos para internalização de enzimas
CL2017003089A1 (es) Formas de dosificación sólidas de palbociclib
UY36723A (es) Composiciones antifúngicas de methylobacterium y sus métodos de uso
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EP3490474A4 (en) ORTHOPEDIC TIED IMPLANTS AND SYSTEM
EA201692105A1 (ru) Новые пиразолопиримидиновые производные и их применение в качестве ингибиторов malt1
PL3658140T3 (pl) Połączenia aprocitentanu z dodatkowymi składnikami czynnymi do leczenia opornego nadciśnienia
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
BR112017005504A2 (pt) composições que compreendem células recombinantes de bacillus e um inseticida.
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
MX388559B (es) Anticuerpo monoclonal humanizado para inhibir la actividad enzimatica de la lipasa endotelial vascular.
EP3492057A4 (en) VOIDABLE ARTICLE
CO2017011778A2 (es) Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden
EA201791716A1 (ru) Фармацевтический состав
MX382864B (es) Formulaciones de anticuerpos cristalinos.
JO3456B1 (ar) فيروتيوكسيتين بيروجلوتامات
CL2019001614S1 (es) Frasco de perfume.
EP3713586A4 (en) VIBRIO SP. ORGANISMS WITH MODIFIED LIPOPOLY SACCHARIDE
ES2722323T3 (es) Composición fertilizante que incluye un inhibidor de la actividad de la ureasa
CL2015002642A1 (es) Anticuerpo monoclonal, inhibiendo la actividad enzimática de la lipasa endotelial vascular.
BR112018004657A2 (pt) composições ativas de alto ph.
EP3459974C0 (en) SPECIFIC INACTIVATION OF PLASMIN BY ANTICATALYTIC ANTIBODY
FR3019047B1 (fr) Diffuseur d&#39;agent parfumant et/ou assainissant active par retournement.